A prospective phase II study of 2-methoxyestradiol administered in combination with bevacizumab in patients with metastatic carcinoid tumors

Cancer Chemotherapy and Pharmacology

Volumn 68, Issue 2, 2011, Pages 293-300

  Kulke, Matthew H ^a   Chan, Jennifer A ^a   Meyerhardt, Jeffrey A ^a   Zhu, Andrew X ^b   Abrams, Thomas A ^a   Blaszkowsky, Lawrence S ^b   Regan, Eileen ^a   Sidor, Carolyn ^c   Fuchs, Charles S ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c ENTREMED INC   (United States)

Author keywords

Bevacizumab; Carcinoid; Neuroendocrine Tumors; Sorafenib

Indexed keywords

2 METHOXYESTRADIOL; 5 HYDROXYINDOLEACETIC ACID; BEVACIZUMAB; CHROMOGRANIN A;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ANOREXIA; AREA UNDER THE CURVE; ARTICLE; CANCER SURVIVAL; CARCINOID; CHOLANGITIS; CLINICAL ARTICLE; CONSTIPATION; COUGHING; DEEP VEIN THROMBOSIS; DEHYDRATION; DIARRHEA; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; DYSPHONIA; DYSPNEA; FATIGUE; FEMALE; FLATULENCE; FLUSHING; GASTROINTESTINAL HEMORRHAGE; HUMAN; HYPERTENSION; HYPOXIA; INSOMNIA; LUNG INFECTION; MALE; MAXIMUM PLASMA CONCENTRATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROENDOCRINE TUMOR; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; SIDE EFFECT; SUICIDAL IDEATION; SURVIVAL TIME; SYNCOPE; TIME TO MAXIMUM PLASMA CONCENTRATION; TUMOR REGRESSION; URINARY TRACT INFECTION; VOMITING;

ADULT; AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOID TUMOR; COHORT STUDIES; ESTRADIOL; FEMALE; GASTROINTESTINAL NEOPLASMS; HUMANS; HYDROXYESTRONES; MALE; MIDDLE AGED; NEOPLASM STAGING; PATIENT DROPOUTS; SURVIVAL ANALYSIS; TUMOR BURDEN; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 79960900243     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-010-1478-7     Document Type: Article

References (27)

1. C Moertel M Lefkopoulo S Lipsitz, et al. 1992 Streptozocin-doxorubicin, stretpozocin-fluorouracil, or chlorozotocin in the treatment of advanced islet-cell carcinoma N Engl J Med 326 519 523 1310159 10.1056/ NEJM199202203260804 1:STN:280:DyaK387itlejuw%3D%3D
2. M Kulke J Hornick C Frauenhoffer, et al. 2009 O6-methylguanine DNA methyltransferase deficiency and response to temozolomide-based therapy in patients with neuroendocrine tumors Clin Cancer Res 15 338 345 19118063 10.1158/1078-0432.CCR-08-1476 1:CAS:528:DC%2BD1MXhs1eqsQ%3D%3D
3. S Ekeblad A Sundin ET Janson, et al. 2007 Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors Clin Cancer Res 13 2986 2991 17505000 10.1158/1078-0432.CCR-06-2053 1:CAS:528: DC%2BD2sXlt1Krtro%3D (Pubitemid 46849574)
4. Arnold R, Muller H, Schade-Brittinger C et al (2009) Placebo-controlled, double blind, prospective, randomized study of the efect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID study group. 2009 Gastrointestinal Cancers Symposium A121
5. S Faiss UF Pape M Bohmig, et al. 2003 Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors-the International Lanreotide and Interferon Alfa Study Group J Clin Oncol 21 2689 2696 12860945 10.1200/JCO.2003.12.142 1:CAS:528:DC%2BD2cXptlCktLk%3D (Pubitemid 46606312)
6. J Zhang Z Jia Q Li, et al. 2007 Elevated expression of vascular endothelial growth factor correlates with increased angiogenesis and decreased progression-free survival among patients with low-grade neuroendocrine tumors Cancer 109 1478 1486 17340592 10.1002/cncr.22554 1:CAS:528:DC%2BD2sXlt1GmtL4%3D (Pubitemid 46595681)
7. B Terris J Scoazec L Rubbia 1998 Expression of vascular endothelial growth factor in digestive neuroendocrine tumors Histopathology 32 133 138 9543669 10.1046/j.1365-2559.1998.00321.x 1:STN:280:DyaK1c3gsFamsw%3D%3D (Pubitemid 28126179)
8. Hobday TJ, Rubin J, Holen K et al (2007) MC044 h, a phase II trial of sorafenib in patients (pts) with metastatic neuroendocrine tumors (NET): a Phase II Consortium (P2C) study (abstract). J of Clin Onc ASCO Annual Meeting Proc Part 1 25:4504
9. MH Kulke HJ Lenz NJ Meropol, et al. 2008 Activity of sunitinib in patients with advanced neuroendocrine tumors J Clin Oncol 26 3403 3410 18612155 10.1200/JCO.2007.15.9020 1:CAS:528:DC%2BD1cXpvVWitro%3D
10. JC Yao A Phan PM Hoff, et al. 2008 Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alpha-2b J Clin Oncol 26 1316 1323 18323556 10.1200/JCO.2007.13.6374 1:CAS:528:DC%2BD1cXksVehu7k%3D
11. RA Hughes T Harris E Altmann, et al. 2002 2-Methoxyestradiol and analogs as novel antiproliferative agents: analysis of three-dimensional quantitative structure-activity relationships for DNA synthesis inhibition and estrogen receptor binding Mol Pharmacol 61 1053 1069 11961123 10.1124/mol.61.5.1053 1:CAS:528:DC%2BD38XjtlGlur4%3D (Pubitemid 34441770)
12. T Fotsis Y Zhang MS Pepper, et al. 1994 The endogenous oestrogen metabolite 2-methoxyoestradiol inhibits angiogenesis and suppresses tumour growth Nature 368 237 239 7511798 10.1038/368237a0 1:CAS:528:DyaK2cXitlKns7Y%3D (Pubitemid 24108838)
13. CM Becker N Rohwer T Funakoshi, et al. 2008 2-methoxyestradiol inhibits hypoxia-inducible factor-1{alpha} and suppresses growth of lesions in a mouse model of endometriosis Am J Pathol 172 534 544 18202195 10.2353/ajpath.2008. 061244 1:CAS:528:DC%2BD1cXis1aisL8%3D (Pubitemid 351282038)
14. WL Dahut NJ Lakhani JL Gulley, et al. 2006 Phase I clinical trial of oral 2-methoxyestradiol, an antiangiogenic and apoptotic agent, in patients with solid tumors Cancer Biol Ther 5 22 27 16357512 10.4161/cbt.5.1.2349 1:CAS:528:DC%2BD28XkvVSntro%3D (Pubitemid 43234973)
15. C Sweeney G Liu C Yiannoutsos, et al. 2005 A phase II multicenter, randomized, double-blind, safety trial assessing the pharmacokinetics, pharmacodynamics, and efficacy of oral 2-methoxyestradiol capsules in hormone-refractory prostate cancer Clin Cancer Res 11 6625 6633 16166441 10.1158/1078-0432.CCR-05-0440 1:CAS:528:DC%2BD2MXhtVShsbzN (Pubitemid 41339003)
16. Liu G, sidor C, Feierabend C et al (2005) Phase Ib trial of 2ME2 administered as a nanocrystal dispersion (NCD) in patients with advanced cancer. Proceedings of EORTC/AACR/NCI B14:129
17. Sweeney C, Slebe K, Li M et al (2005) A single center open label dose escalation safety and pharmacokinetic study of 2 methoxyestriadiol nanocrystal colloidal dispersion in patients with advanced cancer. Proceedings of EORTC/AACR/NCI B12:157
18. D Matei J Schilder G Sutton, et al. 2009 Activity of 2 methoxyestradiol (Panzem NCD) in advanced, platinum-resistant ovarian cancer and primary peritoneal carcinomatosis: a Hoosier Oncology Group trial Gynecol Oncol 115 90 96 19577796 10.1016/j.ygyno.2009.05.042 1:CAS:528:DC%2BD1MXhtVKgtrfI
19. G Schumacher M Kataoka JA Roth, et al. 1999 Potent antitumor activity of 2-methoxyestradiol in human pancreatic cancer cell lines Clin Cancer Res 5 493 499 10100698 1:CAS:528:DyaK1MXitVyisLo%3D (Pubitemid 29131956)
20. J Sosman I Puzanov 2009 Combination targeted therapy in advanced renal cell carcinoma Cancer 115 2368 2375 19402058 10.1002/cncr.24234 1:CAS:528:DC%2BD1MXmtVOktrs%3D
21. DR Feldman MS Baum MS Ginsberg, et al. 2009 Phase I trial of bevacizumab plus escalated doses of sunitinib in patients with metastatic renal cell carcinoma. [see comment] J Clin Oncol 27 1432 1439 19224847 10.1200/JCO.2008.19. 0108 1:CAS:528:DC%2BD1MXksF2hs7w%3D
22. CM Korse JM Bonfrer NK Aaronson, et al. 2009 Chromogranin A as an alternative to 5-hydroxyindoleacetic acid in the evaluation of symptoms during treatment of patients with neuroendocrine Tumors Neuroendocrinology 89 296 301 18840995 10.1159/000162876 1:CAS:528:DC%2BD1MXkvV2jsL4%3D
23. JC Yao AT Phan DZ Chang, et al. 2008 Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study. [erratum appears in J Clin Oncol. 2008 Dec 1;26(34):5660] J Clin Oncol 26 4311 4318 18779618 10.1200/JCO.2008.16.7858
24. Raymond E (2009) Phase III randomised double blind trial of suntinib versus placebo in patients with progressive, well-differentiated pancreatic neuroendocrine tumors. World Congress on Gastrointestinal Cancers, Barcelona, Spain
25. MH Kulke EK Bergsland DP Ryan, et al. 2006 Phase II study of recombinant human endostatin in patients with advanced neuroendocrine tumors J Clin Oncol 24 3555 3561 16877721 10.1200/JCO.2006.05.6762 1:CAS:528:DC%2BD28XovVSjs7o%3D (Pubitemid 46630526)
26. I Duran J Kortmansky D Singh, et al. 2006 A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas Br J Cancer 95 1148 1154 17031397 10.1038/sj.bjc.6603419 1:CAS:528: DC%2BD28XhtFChs7vP (Pubitemid 44660065)
27. JC Yao JX Zhang A Rashid, et al. 2007 Clinical and in vitro studies of imatinib in advanced carcinoid tumors Clin Cancer Res 13 234 240 17200360 10.1158/1078-0432.CCR-06-1618 1:CAS:528:DC%2BD2sXotlWj (Pubitemid 46121874)